

## Hybrigenics successfully raised €4.6 million

**Paris, 22 October 2014** – Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in proteomic and genomic scientific services, today announces the successful completion of a private placement for €4.62 million to the Crede Capital Group, llc, a US-based family office, which has completed numerous investments in European life sciences companies.

A total of 3,500,000 new shares have been issued at €1.32 each, representing a 20% discount to the 5-day volume weighted average price of Hybrigenics shares prior to the operation which was completed on the basis of the delegation in place according to the 11<sup>th</sup> resolution voted by the Shareholders' Meeting of June 20, 2014 with respect to private placements to qualified investors or to a small number of investors with the meaning of the paragraph II of article L. 411-2 of the French financial and monetary Code. The new shares are of the same class as existing shares and represent 13.5% of Hybrigenics' capital before the capital raise and 11.9% after.

*"The success of this capital increase by Crede Capital Group, a US family office, demonstrates the attractiveness of Hybrigenics. Hybrigenics combines the clinical development of inecalcitol in orphan adult leukemias, the research collaboration with Servier and the expanding business of proteomic and genomic services. This capital increase will enable Hybrigenics to strengthen its research and clinical development activities,"* said Remi Delansorne, Hybrigenics' CEO.

### About Hybrigenics

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio ([www.helixio.com](http://www.helixio.com)), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

### Disclaimer

*This announcement is for information purposes only and does not, and shall not, in any circumstances, constitute a public offering by Hybrigenics nor a solicitation of an offer to subscribe for securities in any jurisdiction, including France.*

*In particular, this announcement and the information contained herein do not constitute an offer or solicitation of an offer to subscribe for securities in the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration under*

**This press release may not be published, forwarded or distributed, directly or indirectly, in the United States, Canada, Australia or Japan**

# HYBRIGENICS

## Press Release

*the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The shares of Hybrigenics have not been and will not be registered under the U.S. Securities Act and Hybrigenics does not intend to register securities or conduct a public offering in the United States.*

*With respect to the member states of the European Economic Area which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003, as amended, in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010 (the "Prospectus Directive"), no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member state.*

*In the United Kingdom, this document is only being distributed to, and is only directed at, persons that are "qualified investors" within the meaning of Article 2(1)(e)(i), (ii) or (iii) of the Prospectus Directive and that also (i) are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, this document must not be acted on or relied on by persons who are not relevant persons.*

*In accordance with Article 211-3 of the General Regulation of the AMF, it is recalled that the above mentioned private placement and share capital increase do not require a prospectus to be submitted for approval to the AMF.*

*The distribution of this announcement in certain countries may be subject to specific regulations. The persons in possession of this announcement shall then get knowledge of any local restrictions and shall comply with these restrictions.*

*Any decision to subscribe for Hybrigenics shares should only be made on the basis of public information about Hybrigenics.*

\*\*\*

**HYBRIGENICS is listed on the Alternext market of Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



**Hybrigenics**  
Rémi Delansorne  
CEO  
Tel.: +33 (0)1 58 10 38 00  
investors@hybrigenics.com

**NewCap**  
Financial communication  
Julien Perez / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
hybrigenics@newcap.fr

**This press release may not be published, forwarded or distributed, directly or indirectly, in the United States, Canada, Australia or Japan**